RT Journal Article
T1 Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
A1 Cuneo, Antonio
A1 Mato, Anthony R
A1 Rigolin, Gian Matteo
A1 Piciocchi, Alfonso
A1 Gentile, Massimo
A1 Laurenti, Luca
A1 Allan, John N
A1 Pagel, John M
A1 Brander, Danielle M
A1 Hill, Brian T
A1 Winter, Allison
A1 Lamanna, Nicole
A1 Tam, Constantine S
A1 Jacobs, Ryan
A1 Lansigan, Frederick
A1 Barr, Paul M
A1 Shadman, Mazyar
A1 Skarbnik, Alan P
A1 Pu, Jeffrey J
A1 Sehgal, Alison R
A1 Schuster, Stephen J
A1 Shah, Nirav N
A1 Ujjani, Chaitra S
A1 Roeker, Lindsey
A1 Orlandi, Ester Maria
A1 Billio, Atto
A1 Trentin, Livio
A1 Spacek, Martin
A1 Marchetti, Monia
A1 Tedeschi, Alessandra
A1 Ilariucci, Fiorella
A1 Gaidano, Gianluca
A1 Doubek, Michael
A1 Farina, Lucia
A1 Molica, Stefano
A1 Di Raimondo, Francesco
A1 Coscia, Marta
A1 Mauro, Francesca Romana
A1 de la Serna, Javier
A1 Medina Perez, Angeles
A1 Ferrarini, Isacco
A1 Cimino, Giuseppe
A1 Cavallari, Maurizio
A1 Cucci, Rosalba
A1 Vignetti, Marco
A1 Foà, Robin
A1 Ghia, Paolo
A1 GIMEMA, European Research Initiative (ERIC) on CLL, US study group
K1 bendamustine
K1 chronic lymphocytic leukemia
K1 ibrutinib
K1 real-world analysis
K1 unfit patients
AB Limited information is available on the efficacy of front-line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real-world patients and performed a matched adjusted indirect comparison with a cohort of patients treated with ibrutinib. One hundred and fifty-seven patients with creatinine clearance (CrCl) 6 were treated with BR. The median age was 72 years; 69% of patients had ≥2 comorbidities and the median CrCl was 59.8 mL/min. 17.6% of patients carried TP53 disruption. The median progression-free survival (PFS) was 45 months; TP53 disruption was associated with a shorter PFS (P = 0.05). The overall survival (OS) at 12, 24, and 36 months was 96.2%, 90.1%, and 79.5%, respectively. TP53 disruption was associated with an increased risk of death (P = 0.01). Data on 162 patients ≥65 years treated with ibrutinib were analyzed and compared with 165 patients ≥65 years treated with BR. Factors predicting for a longer PFS at multivariable analysis in the total patient population treated with BR and ibrutinib were age (HR 1.06, 95% CI 1.02-1.10, P 
YR 2020
FD 2020-09-24
LK https://hdl.handle.net/10668/26640
UL https://hdl.handle.net/10668/26640
LA en
DS RISalud
RD Apr 5, 2025